Endocannabinoids and cardiac contractile function: Pathophysiological implications
- 1 August 2009
- journal article
- review article
- Published by Elsevier in Pharmacological Research
- Vol. 60 (2) , 99-106
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?Trends in Pharmacological Sciences, 2009
- Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferationBiochemical and Biophysical Research Communications, 2008
- Measurement of cardiac function using pressure–volume conductance catheter technique in mice and ratsNature Protocols, 2008
- Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioningBritish Journal of Pharmacology, 2008
- Multiple pathways involved in the biosynthesis of anandamideNeuropharmacology, 2008
- The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effectsBritish Journal of Pharmacology, 2007
- The contribution of cyclooxygenase‐2 to endocannabinoid metabolism and actionBritish Journal of Pharmacology, 2007
- Pharmacological Inhibition of CB1Cannabinoid Receptor Protects Against Doxorubicin-Induced CardiotoxicityJACC, 2007
- Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusionsBritish Journal of Pharmacology, 2007
- Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptorsBritish Journal of Pharmacology, 2006